© 2005 European Society of Cardiology
Baseline characteristics of patients recruited into the CARE-HF study
Department of Cardiology, Castle Hill Hospital Castle Road, Cottingham, University of Hull Kingston upon Hull, UK HU16 5JQ
* Corresponding author. Tel.: +44 1482 624084; fax: +44 1482 624085. E-mail address: J.G.Cleland{at}hull.ac.uk
 |
Abstract |
|---|
Background: Cardiac resynchronisation therapy (CRT) is a promising new treatment for patients with heart failure and cardiac dyssynchrony. The CARE-HF study is a morbidity/mortality trial designed to provide conclusive evidence of the effects of CRT in patients with moderate to severe heart failure.
Methods: A description of the baseline characteristics of patients randomised in the CARE-HF trial.
Results: 813 Patients with predominantly NYHA class III (94%) heart failure were randomised in 82 centres. Their mean age was 65 (interquartile range [IQR] 59 to 72) years, 34% were aged >70 years and 27% were women. Thirty-eight percent of the patients had ischaemic heart disease. Mean heart rate was adequately controlled at 70 (IQR 60 to 78) bpm consistent with the use of beta-blockers. Supine systolic blood pressure was low at 117 (IQR 105 to 130) mm Hg. Eighty-eight percent of patients had a QRS 
150 ms. Mean LV ejection fraction was 26% (IQR 22 to 29) and end-diastolic dimension was 7.2 (IQR 6.4 to 7.8) cm. Ninety-four percent of patients were receiving loop diuretics, 95% an ACE inhibitor or angiotensin receptor blocker (ARB), 72% a beta-blocker and 56% were taking spironolactone.
Conclusions: The patients enrolled in CARE-HF had moderately severe heart failure and cardiac dysfunction with evidence of cardiac dyssynchrony. The population appears at high risk of events despite pharmacological therapy and therefore appropriate for a trial of CRT.
Key Words: Heart failure • Cardiac resynchronisation therapy • Dyssynchrony • Mortality and morbidity • Randomized or randomised
Received December 23, 2004; Accepted January 13, 2005
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Schmidt, H. Rittger, H. Marschang, A.-M. Sinha, M. Daccarett, J. Brachmann, M. Block, and O. A. Breithardt Left ventricular dyssynchrony from right ventricular pacing depends on intraventricular conduction pattern in intrinsic rhythm Eur J Echocardiogr, August 1, 2009; 10(6): 776 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Laveneziana, D. E. O'Donnell, D. Ofir, P. Agostoni, L. Padeletti, G. Ricciardi, P. Palange, R. Duranti, and G. Scano Effect of biventricular pacing on ventilatory and perceptual responses to exercise in patients with stable chronic heart failure J Appl Physiol, May 1, 2009; 106(5): 1574 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghio, N. Freemantle, L. Scelsi, A. Serio, G. Magrini, M. Pasotti, A. Shankar, J. G.F. Cleland, and L. Tavazzi Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial Eur J Heart Fail, May 1, 2009; 11(5): 480 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland, L. Tavazzi, J.-C. Daubert, A. Tageldien, and N. Freemantle Cardiac resynchronization therapy are modern myths preventing appropriate use? J. Am. Coll. Cardiol., February 17, 2009; 53(7): 608 - 611. [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Marwick and M. Schwaiger The Future of Cardiovascular Imaging in the Diagnosis and Management of Heart Failure, Part 2: Clinical Applications Circ Cardiovasc Imaging, September 1, 2008; 1(2): 162 - 170. [Full Text] [PDF]
|
|
|
|
|
|
P. Blomstrom, M. Ekman, C. B. Lundqvist, M.J. Calvert, N. Freemantle, S. Lonnerholm, G. Wikstrom, and B; Jonsson Cost effectiveness of cardiac resynchronization therapy in the Nordic region: An analysis based on the CARE-HF trial Eur J Heart Fail, September 1, 2008; 10(9): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cleland, N. Freemantle, S. Ghio, F. Fruhwald, A. Shankar, M. Marijanowski, Y. Verboven, and L. Tavazzi Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response: A Report From the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial J. Am. Coll. Cardiol., August 5, 2008; 52(6): 438 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Chung, R Sutton, and M Y Henein Beyond dyssynchrony in cardiac resynchronisation therapy Heart, August 1, 2008; 94(8): 991 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Marwick Hype and Hope in the Use of Echocardiography for Selection for Cardiac Resynchronization Therapy: The Tower of Babel Revisited Circulation, May 20, 2008; 117(20): 2573 - 2576. [Full Text] [PDF]
|
|
|
|
|
|
J G F Cleland, N Freemantle, J-C Daubert, W D Toff, F Leisch, and L Tavazzi Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study Heart, March 1, 2008; 94(3): 278 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Fruhwald, A. Fahrleitner-Pammer, R. Berger, F. Leyva, N. Freemantle, E. Erdmann, D. Gras, L. Kappenberger, L. Tavazzi, J.-C. Daubert, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony Eur. Heart J., July 1, 2007; 28(13): 1592 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gras, D. Bocker, M. Lunati, H.J.J. Wellens, M. Calvert, N. Freemantle, R. Gervais, L. Kappenberger, L. Tavazzi, E. Erdmann, et al. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety Europace, July 1, 2007; 9(7): 516 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Inglis, S. Stewart, A. Papachan, V. Vaghela, C. Libhaber, Y. Veriava, and K. Sliwa Anaemia and renal function in heart failure due to idiopathic dilated cardiomyopathy Eur J Heart Fail, April 1, 2007; 9(4): 384 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. C. Hoppe, N. Freemantle, J. G.F. Cleland, M. Marijianowski, and E. Erdmann Effect of Cardiac Resynchronization on Morbidity and Mortality of Diabetic Patients With Severe Heart Failure Diabetes Care, March 1, 2007; 30(3): 722 - 724. [Full Text] [PDF]
|
|
|
|
|
|
M. Schmidt, J. Bromsen, C. Herholz, K. Adler, F. Neff, C. Kopf, and M. Block Evidence of left ventricular dyssynchrony resulting from right ventricular pacing in patients with severely depressed left ventricular ejection fraction Europace, January 1, 2007; 9(1): 34 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghio, N. Freemantle, A. Serio, G. Magrini, L. Scelsi, M. Pasotti, J. G.F. Cleland, and L. Tavazzi Baseline echocardiographic characteristics of heart failure patients enrolled in a large European multicentre trial (CArdiac REsynchronisation Heart Failure study) Eur J Echocardiogr, October 1, 2006; 7(5): 373 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, J.-C. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, L. Tavazzi, and on behalf of The CARE-HF Study Investigators Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase] Eur. Heart J., August 2, 2006; 27(16): 1928 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Hoppe, J. M. Casares, H. Eiskjaer, A. Hagemann, J. G.F. Cleland, N. Freemantle, and E. Erdmann Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure Circulation, July 4, 2006; 114(1): 18 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. Charlesworth, J. Lubsen, K. Swedberg, W. J. Remme, L. Erhardt, A. Di Lenarda, M. Komajda, M. Metra, C. Torp-Pedersen, et al. A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure: A Report From the Carvedilol Or Metoprolol European Trial (COMET) J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1603 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, K. Goode, O. Khaleva, and N. Khan How many patients need cardiac resynchronization therapy? Eur. Heart J., February 1, 2006; 27(3): 251 - 252. [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, M. Lammiman, K. K. Witte, H. Loh, M. Nasir, and A. L. Clark Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE Eur J Heart Fail, October 1, 2005; 7(6): 1070 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, N. Freemantle, P. Velavan, L. Tin, and A. L. Clark Clinical trials update from the American College of Cardiology meeting: CARE-HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER Eur J Heart Fail, August 1, 2005; 7(5): 931 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Kirkorian, H. Burri, J. G.F. Cleland, J.-C. Daubert, L. Tavazzi, and the CARE-HF Study Investigators Cardiac-Resynchronization Therapy in Heart Failure N. Engl. J. Med., July 14, 2005; 353(2): 205 - 206. [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, J.-C. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, L. Tavazzi, and the Cardiac Resynchronization -- Heart Failure (CA The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure N. Engl. J. Med., April 14, 2005; 352(15): 1539 - 1549. [Abstract] [Full Text] [PDF]
|
|